Loading...
Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts
It is becoming clear that combination strategies will be necessary to augment cancer immunotherapy. We report that combination anti-OX40/anti-CTLA-4 mAb immunotherapy improves survival by enhancing effector T cell expansion and function, even while inducing Th2 cytokine production. Furthermore, IL-4...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Landes Bioscience
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4091104/ https://ncbi.nlm.nih.gov/pubmed/25050194 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.28245 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|